Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8907908 | 1.00 | DGAT1 (0.33) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL10614000 | 0.83 | DGAT1 (0.34) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL10613987 | 0.83 | DGAT1 (0.34) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL27925918 | 0.78 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL4529907 | 0.76 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL25087377 | 0.76 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL741932 | 0.76 | DGAT1 (0.34) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL10936589 | 0.76 | CTSK (0.35) | DGAT1CTSKMAOAMAOB | |
| SCHEMBL8188812 | 0.76 | CYP2C9 (0.31) | DGAT1 | |
| SCHEMBL27461003 | 0.74 | CTSK (0.30) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-0910563-B1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-0977735-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6191304-B1 | REDUCTION OF AN ALKYL 3-ALKYLOXY-11-OXO-10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-10-ACETATE BY HYDROGENOLYSIS USING A PALLADIUM/ACTIVATED CARBON CATALYST; INTERMEDIATES FOR3-((4-AMINOPYRID-2-YL)AMINOALKYLENEOXY) DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-6069158-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0977735-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0977735-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-09 | — | — | EP | disclosed |
| US-6008213-A | A INHIBITOR OF VITRONECTIN RECEPTOR AND FIBRINOGEN RECEPTOR; USEFUL FOR INHIBITING PLATELET AGGREGATION AND OSTEOPOROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0910563-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0910563-A4 | — | — | 1999-04-28 | — | — | EP | disclosed |
| EP-0831830-A4 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998030542-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997001540-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | DGAT1 3566/4885CTSK 1550/4885MAOA 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.